阿托伐他汀对冠心病心绞痛患者CXCL型趋化因子及血管内皮损伤指标的影响

赵貤; 晏子俊

阿托伐他汀对冠心病心绞痛患者CXCL型趋化因子及血管内皮损伤指标的影响

赵貤,
晏子俊

攀枝花市中心医院药学部

基金项目:

基金：四川省科学技术研究与发展计划基金资助项目 (MSD2017003);

计量
- 文章访问数: 1916
- HTML全文浏览量: 655
- PDF下载量: 44
- 被引次数: 0
出版历程
- 收稿日期: 2018-04-21

A Study on the Influence of Atorvastatin for the CXCL Chemokines and Vascular Endothelial Damage Indexes of Patients with Angina Pectoris of Coronary Heart Disease

Zhao Yi,
Yan Zi Jun

Funds:

基金：四川省科学技术研究与发展计划基金资助项目 (MSD2017003);

摘要

摘要: 目的观察阿托伐他汀对冠心病心绞痛患者CXCL型趋化因子及血管内皮损伤指标的影响.方法选取2016年2月至2017年7月期间攀枝花市中心医院收治的86例冠心病心绞痛患者为研究对象, 将所有患者根据随机数字表法分为对照组和观察组每组各43例.对照组在常规治疗的基础上加用辛伐他汀, 观察组则在常规治疗的基础上加用阿托伐他汀.统计与比较2组患者的心绞痛治疗效果、不良反应发生率、治疗前后的CXCL型趋化因子及血管内皮损伤指标.结果观察组的心绞痛治疗总有效率显著高于对照组, 差异有统计学意义 (P<0.05) , 2组的不良反应发生率比较, 差异无统计学意义 (P>0.05) , 治疗前2组患者的血清CXCL型趋化因子及血管内皮损伤指标比较, 差异无统计学意义 (P>0.05) , 治疗后观察组的血清PGI2水平高于对照组, 血清CXCL型趋化因子及其他血管内皮损伤指标低于对照组, 差异有统计学意义 (P<0.05) .结论阿托伐他汀在冠心病心绞痛患者中的治疗效果较好, 安全性较高, 且对CXCL型趋化因子及血管内皮损伤指标具有较好的改善作用, 因此在冠心病心绞痛患者中具有较高的应用价值.
- 阿托伐他汀 /
- 冠心病心绞痛 /
- CXCL型趋化因子 /
- 血管内皮损伤指标
Abstract: Objective To study and observe the influence of atorvastatin for the CXCL chemokines and vascular endothelial damage indexes of patients with angina pectoris of coronary heart disease.Methods 86 patients with angina pectoris of coronary heart disease in our hospital from February 2016 to July 2017 were selected as the study objects, and all the patients were divided into the control group and the observation group with 43 cases in each group according to the random number table.The control group were treated with simvastatin on the basis of routine treatment, and the observation group were treated with atorvastatin on the basis of routine treatment.Then the treatment effect of angina pectoris, adverse reaction rates, CXCL chemokines and vascular endothelial damage indexes before and after the treatment of two groups were analyzed and compared.Results The total effective rate of observation group with angina pectoris was significantly higher than that of control group, so the difference had statistical significance (P<0.05) , the adverse reaction rates of two groups were compared, so the difference had no statistical significance (P>0.05) , the CXCL chemokines and vascular endothelial damage indexes of two groups before the treatment were compared, and the differenceshad no statistical significance (P>0.05) , the serum PGI2 of observation group after the treatment were lower than those of control group, the serum CXCL chemokines and other vascular endothelial damage indexes were lower than those of control group, and the differences had statistical significance (P<0.05) . Conclusions The treatment effect of atorvastatin in the patients with angina pectoris of coronary heart disease is better, and its safety is higher, and it has a better improvement role for the CXCL chemokines and vascular endothelial damage indexes, so it has a higher application value in the patients with angina pectoris of coronary heart disease.
- Torvastatin /
- Angina pectoris of coronary heart disease /
- CXCL chemokines /
- Vascular endothelial damage indexes

HTML全文

参考文献(21)

[1]王俊霞.阿托伐他汀联合曲美他嗪治疗冠心病的临床观察[J].中国现代药物应用, 2016, 10 (17) :133-134.
[2]高阿妮.观察阿托伐他汀与曲美他嗪联用治疗冠心病的临床疗效[J].航空航天医学杂志, 2016, 27 (4) :483-484.
[3]胡大一.冠心病诊断与治疗研究进展[J].中华心血管病杂志, 2003, 31 (11) :806-811.
[4]钟雨霞.阿托伐他汀钙联合曲美他嗪治疗冠心病的有效性及安全性观察[J].医学理论与实践, 2016, 29 (13) :1719-1720.
[5]贾智, 唐金国, 廖礼强.阿托伐他汀对冠心病患者心室重塑及其相关血清指标的影响[J].西部医学, 2015, 27 (3) :403-404.
[6]李林贵.瑞舒伐他汀与阿托伐他汀对冠心病患者血hs-CRP、Hcy及IMT的影响比较[J].心脑血管病防治, 2015, 15 (5) :409-410.
[7]	[7]CAROSELLI C, DE ROSA R, TANZI P, et al.Endothelial immunomediated reactivity in acute cardiac ischaemia:Role of endothelin 1, interleukin 8 and NT-pro BNP in patients affected by unstable angina pectoris[J].Int J Immunopathol Pharmacol, 2016, 29 (3) :516-522.
[8]袁洪雨.曲美他嗪、阿托伐他汀联合使用对冠心病不稳定型心绞痛的治疗效果观察[J].中西医结合心血管病杂志 (电子版) , 2017, 5 (3) :39.
[9]王桂玲.氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的疗效观察[J].中西医结合心血管病杂志 (电子版) , 2017, 5 (7) :15-16.
[10]王茜, 闵新文, 李东峰, 等.阿托伐他汀对冠心病患者炎症因子和血管内皮功能的疗效[J].心血管康复医学杂志, 2017, 26 (4) :420-424.
[11]	[11]LISOWSKA A, LISOWSKI P, KNAPP M, et al.Serum adiponectin and markers of endothelial dysfunction in stable angina pectoris patients undergoing coronary artery bypass grafting (CABG) [J].Adv Med Sci, 2014, 59 (2) :245-249.
[12]刘颖.阿托伐他汀联合曲美他嗪治疗冠心病80例的临床效果分析[J].中西医结合心血管病杂志 (电子版) , 2016, 4 (25) :65.
[13]马强, 崔国雄.阿托伐他汀联合曲美他嗪对冠心病患者心功能、炎性因子及血管内皮功能的影响[J].实用临床医药杂志, 2016, 20 (23) :5-8.
[14]	[14]KABAKLI A, FRAS Z.Moderate-dose atorvastatin improves arterial endothelial function in patients with angina pectoris and normal coronary angiogram:A pilot study[J].Arch Med Sci, 2017, 3 (4) :827-836.
[15]祝盛善, 王庆春, 胡坚.冠心病不稳定心绞痛治疗前后血清趋化因子CXCL16检测的临床意义[J].临床合理用药杂志, 2015, 8 (8) :88-89.
[16]祝盛善, 胡坚.CXC趋化因子配体16和同型半胱氨酸联合检测在冠心病诊疗中的意义[J].山西医药杂志, 2014, 43 (17) :2088-2090.
[17]卢亚敏, 霍丽静, 张明明, 等.不同类型冠心病合并2型糖尿病患者趋化因子和氧化应激分子水平的研究[J].中国基层医药, 2016, 23 (14) :2107-2110.
[18]陆振涛.瑞舒伐他汀与阿托伐他汀对冠心病急性心肌梗死患者血管内皮功能的影响[J].医药论坛杂志, 2015, 36 (11) :40-42.
[19]	[19]SHEPHERD J, BREAZNA A, DEEDWANIA P C, et al.Relation between change in renal function and cardiovascular outcomes in atorvastatin-treated patients (from the Treating to New Targets[TNT]study) [J].Am J Cardiol, 2016, 117 (8) :1199-1205.
[20]	[20]GUNDAPANENI KK, SHYAMALA N, GALIMUDI RK, et al.A therapeutic effects of atorvastatin on genetic damage in coronary artery disease[J].J Clin Diagn Res, 2016, 10 (6) :28-30.
[21]	[21]WEISS M C, BERGER J S, GIANOS E, et al.Lipoprotein (a) screening in patients with controlled traditional risk factors undergoing percutaneous coronary intervention[J].J Clin Lipidol, 2017, 11 (5) :1177-1180.

相关文章(20)

[1]	李思琪, 邰文琳. 趋化因子CXCL10作为肝硬化生物标志物的意义, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20220711
[2]	唐菁, 黄俊超, 黄亚非, 耿明珠, 毛小琴, 普建平. 磷脂酶相关脂蛋白A2在冠心病患者服用他汀类药物时的应用, 昆明医科大学学报. doi: 10.12259/j.issn.2095-610X.S20211205
[3]	孙行云, 刘霞, 孟繁兴, 王乐, 王凤丽. 联合血塞通对比单纯西药治疗脑梗临床疗效的Meta分析, 昆明医科大学学报.
[4]	董丹红, 庞玺倬, 李琳. PKG信号通路在ACS患者PCI术后血管内皮损伤中作用, 昆明医科大学学报.
[5]	王璐, 陈洁, 孔维龙, 喻明丽. 阿托伐他汀联合HRZ致肝损伤生化特点, 昆明医科大学学报.
[6]	李璠, 童宗武, 杨崇猛, 李娟娟, 袁云, 吴春云. 血管内皮生长因子在急性甲醇中毒大鼠大脑皮质的表达变化, 昆明医科大学学报.
[7]	伏忠阳, 易婧. 氨氯地平阿托伐他汀钙片治疗高血压合并冠心病的临床观察, 昆明医科大学学报.
[8]	赵瑜. 人血管内皮生长因子A（VEGFA）的原核载体构建、蛋白表达及鉴定, 昆明医科大学学报.
[9]	周凯华. 2型糖尿病并冠心病患者骨保护素及TGF-β1与糖代谢指标的相关性, 昆明医科大学学报.
[10]	秦敏丽. 不同焦虑状态对糖尿病患者炎性因子及血管内皮功能的影响, 昆明医科大学学报.
[11]	杨萍. 体外心脏震波治疗对冠心病患者血管再生相关细胞因子的影响, 昆明医科大学学报.
[12]	章体玲. 阿托伐他汀对高血压合并房颤患者脉压及动脉弹性的临床疗效观察, 昆明医科大学学报.
[13]	李虹道. 他汀强化治疗的2型糖尿病患者并发冠心病的危险因素分析, 昆明医科大学学报.
[14]	伏忠阳. 丹红注射液与阿托伐他汀联合治疗不稳定型心绞痛效果分析, 昆明医科大学学报.
[15]	李福萍. 阿伐他汀对原发性高血压患者硫化氢和一氧化氮水平的影响, 昆明医科大学学报.
[16]	颜文飞. 阿托伐他汀治疗老年高脂血症的临床疗效及安全性, 昆明医科大学学报.
[17]	. 云南白药对骨折愈合过程中血管内皮生长因子表达的影响, 昆明医科大学学报.
[18]	. 普罗布考治疗动脉粥样硬化40例临床疗效观察, 昆明医科大学学报.
[19]	. 20(R)-人参皂苷Rg3抗血小板活化因子诱导血管内皮细胞损伤的保护作用, 昆明医科大学学报.
[20]	. 阿托伐他汀联合阿司匹林治疗血栓形成性脑梗死患者C反应蛋白及血脂的变化, 昆明医科大学学报.